Literature DB >> 10427941

Tumor progression, early diagnosis and prognosis of melanoma.

D Elder1.   

Abstract

Primary melanomas evolve from melanocytes or from precursor lesions through two stages: the radial and vertical growth phases. The radial growth phase may be in situ or microinvasive, but is a non-tumorigenic neoplastic process, while the vertical growth phase is tumorigenic. The prognosis in radial growth phase is excellent irrespective of thickness or other variables. Curable radial growth phase melanomas can be recognized by surveillance of patients identified by screening for risk markers which include dysplastic nevi, common nevi, freckles, and other indicators of chronic or acute sun exposure or sun sensitivity. The prognosis in vertical growth phase depends on attributes of the tumor and of the host. The tumor mitotic rate, the presence of host tumor-infiltrating lymphocytes (TIL) within the vertical growth phase, and tumor thickness are the most powerful predictors of survival. New prognostic attributes are needed not only to provide for more accurate prognosis and diagnosis, but also to test the relevance of in vitro or animal studies in a human neoplastic system. Such attributes will be developed in the future based on markers that are associated with tumor progression. Candidate markers include growth factors and cytokines and their receptors, adhesion molecules and their ligands, chemotactic and motility factors, immune response-related molecules, and tumor-associated proteases. Some of these markers that are represented in the transition from radial to vertical growth phase will be reviewed. The tumor progression model presented here has been of value in the development of more accurate prognostic models, and in the elucidation of mechanisms of the malignant phenotype in melanoma.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10427941     DOI: 10.1080/028418699431113

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  14 in total

Review 1.  Lymphocyte subpopulation and dendritic cell phenotyping during antineoplastic therapy in human solid tumors.

Authors:  Sara Mariucci; Bianca Rovati; Mariangela Manzoni; Matteo Giovanni Della Porta; Giuditta Comolli; Sara Delfanti; Marco Danova
Journal:  Clin Exp Med       Date:  2010-12-16       Impact factor: 3.984

Review 2.  Transcription factors and other dysregulated proteins in melanoma prognosis.

Authors:  J M Karjalainen
Journal:  Curr Oncol Rep       Date:  2001-07       Impact factor: 5.075

Review 3.  Use of liposomes as drug delivery vehicles for treatment of melanoma.

Authors:  Melissa A Tran; Rebecca J Watts; Gavin P Robertson
Journal:  Pigment Cell Melanoma Res       Date:  2009-05-22       Impact factor: 4.693

Review 4.  The role of integrins in melanoma: a review.

Authors:  Suzette M Arias-Mejias; Katerina Y Warda; Enrica Quattrocchi; Hector Alonso-Quinones; Sindhuja Sominidi-Damodaran; Alexander Meves
Journal:  Int J Dermatol       Date:  2020-03-10       Impact factor: 2.736

5.  Tumor lymphangiogenesis: a novel prognostic indicator for cutaneous melanoma metastasis and survival.

Authors:  Soheil S Dadras; Thomas Paul; Jennifer Bertoncini; Lawrence F Brown; Alona Muzikansky; David G Jackson; Ulf Ellwanger; Claus Garbe; Martin C Mihm; Michael Detmar
Journal:  Am J Pathol       Date:  2003-06       Impact factor: 4.307

6.  Inflammatory tumour cell killing by oncolytic reovirus for the treatment of melanoma.

Authors:  F Errington; C L White; K R Twigger; A Rose; K Scott; L Steele; L J Ilett; R Prestwich; H S Pandha; M Coffey; P Selby; R Vile; K J Harrington; A A Melcher
Journal:  Gene Ther       Date:  2008-04-10       Impact factor: 5.250

7.  Quantitative visualization and detection of skin cancer using dynamic thermal imaging.

Authors:  Cila Herman; Muge Pirtini Cetingul
Journal:  J Vis Exp       Date:  2011-05-05       Impact factor: 1.355

8.  Nuclear ING2 expression is reduced in human cutaneous melanomas.

Authors:  F Lu; D L Dai; M Martinka; V Ho; G Li
Journal:  Br J Cancer       Date:  2006-06-06       Impact factor: 7.640

9.  Emerging technologies for the detection of melanoma: achieving better outcomes.

Authors:  Cila Herman
Journal:  Clin Cosmet Investig Dermatol       Date:  2012-11-12

Review 10.  Nanotechnology in dermatology.

Authors:  João Roberto Antonio; Carlos Roberto Antônio; Izabela Lídia Soares Cardeal; Julia Maria Avelino Ballavenuto; João Rodrigo Oliveira
Journal:  An Bras Dermatol       Date:  2014 Jan-Feb       Impact factor: 1.896

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.